PRYTEK
23.7.2021 03:02:11 CEST | Business Wire | Press release
Aligned with Prytek’s strategy on building technologies and delivering managed services, it is building a new software testing arm by merging its own Technological company prooV™ with QAssure, a leading Asia based software testing company. After the merger Prytek will be the major shareholder providing software testing and prooV™ of Concept as a Service to the global market. Prytek is leading with the concept of BOPaaS (Business Operating Platform as Service) where it is lifting out entire operations from corporates providing them an entire operational solution based on Prytek technologies. The group operated in several sectors such as Financial Services, Cyber & Tech Education and HR sectors. This concept helps CEOs focus on their core business and outsource all banking regulations, software, and education requirements to Prytek.
QAssure and prooV™ announced their agreement to merge under the name of QAssure with Durairaj Dhanasekaran as its CEO. QAssure market-leading testing company head quartered in Singapore with a continuous testing technology platform and managed service capability. prooV™ owned by Prytek, is the first and only end-to-end proof-of-concept platform for third-party software, enabling global enterprises to evaluate and adopt the right new technologies safely, at a fraction of the time and cost. The combined services represent the most modern platform for accelerating open innovation and transforming software testing to keep pace with digital transformation. The combined entity will have a global presence with offices in Asia, the US, and EMEA. This integration will reflect the commitment to innovation and customer success that both companies share.
Andrey Yashunsky CEO of Prytek says “With this merger, we are creating deep tech proof of concept and digital assurance platform company that help accelerate and fast-track open innovation. With a strong implementation support centre based in Singapore, an R&D team based out of Israel and an offshore development team based out of India, we will be able to bring the best minds to build and deliver great technology and services addressing the global customer needs.”
Toby Olshanetsky, CEO and co-founder of prooV™ adds "We are very excited with this merger, in prooV™ we created the first PoC as a Service platform and now we create the first full end to end solution for technology & innovation adoption, using prooV™ and QAssure we provide a 360 offering: before, during and after the POC, enterprises can assess and test multiple technologies simultaneously to identify feature sets, scaling challenges, performance bottlenecks, and security risks before releasing an application to production".
According to Technavio, the global software testing services market has the potential to grow by USD 34.49 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 12.39%. Enterprises have started focusing more on Quality Assurance, which can be gained by the implementation of agile solutions, leading to significant investments for the advancement of the latest quality assurance & software testing services.
About QAssure:
QAssure Technologies is an Independent Software Testing Company founded in 2005. Headquartered in Singapore with an expanding presence in India, Malaysia, Indonesia and the USA, QAssure Technologies focuses on specialized QA Engineering and Testing services with continuous autonomous validation and verification platform. QAssure Technologies brings together the essential combinations of value-driven robust domain knowledge, platforms and exceptional technical capabilities and burgeoning strategic alliances for leading IT solutions. Our expanding global footprint makes it possible for us to meet the software testing demands with versatile delivery models and specialized resources.
About Proov:
prooV™ is the first and only end-to-end proof-of-concept platform for third-party software, enabling global enterprises to evaluate and adopt the right new technologies safely, at a fraction of the time and cost. prooV consolidates the PoC process into one end-to-end ecosystem. With its simplified configuration and single point of integration, prooV enables companies to complete PoCs within days, not months, to run multiple PoCs simultaneously and to quickly evaluate different technology solutions from pre-screened vendors. prooV is the must-have solution for any organization looking to fast-track innovation.
About Prytek:
Prytek is a multinational technology group that builds deep technology and SaaS solutions through a BOPaaS (Business Operating Platform-as-a-Service) which is a combination of Deep Tech Solutions with Managed Services and Capital, providing the capability to lift out entire operations to create more efficient businesses of the future. Headed by industry experts, Prytek builds businesses and ecosystems in the Financial Services, Cyber & Tech Education and HR sectors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005855/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom